Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CAN1012

Phase 2Small molecule

CCanwell Biotech Limited

CAN1012 is one of 88 small molecule programs targeting Solid Tumors. It is currently in Phase 2.

3

Indications

4

Total Trials

3

Active Trials

87

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorsUnknown status

Patients With Solid TumorsRecruiting

Ductal Carcinoma in SituRecruiting

Solid TumorsPhase 1

Unknown status

Patients With Solid TumorsPhase 2

Recruiting

Ductal Carcinoma in SituPhase 1

Recruiting

Competition

Competitive Landscape

124 competitors in Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Lynparza

Lenvima

Opdivo

Bristol-Myers Squibb

Imfinzi

Herceptin

Yervoy

Bristol-Myers Squibb

Fludara

Camptosar

Sutent

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2035

Phase 1Recruiting

Ductal Carcinoma in Situ

NCT07408856

Clinical

Trials by Indication[1]

Solid Tumors2 trials

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

Unknown status·CCanWell Pharma Inc.·Phase 1·NCT04987112·36 enrolled

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

Active, not recruiting·CCanwell Biotech Limited·Phase 1·NCT05580991·27 enrolled

Patients With Solid Tumors1 trial

CAN1012 Combined With PD-1 in Patients With Solid Tumors

Recruiting·CCanwell Biotech Limited·Phase 1/2·NCT06410703·71 enrolled

Ductal Carcinoma in Situ1 trial

A Phase I/Ib Study Evaluating Intralesional TLR7 Agonist, CAN1012, in Pre-malignant Ductal Carcinoma in Situ and Lobular Carcinoma in Situ

Recruiting·PProvidence Health & Services·Phase 1·NCT07408856·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for CAN1012. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAN1012 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAN1012. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Canwell Biotech Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCanwell Biotech Limited

Related News